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Abstract
Genomics research findings on asthma are reported with
increasing frequency. As these findings are incorporated
into existing knowledge of disease etiology and pathogene-
sis, the implications for public health practice need to be
considered. In 2003, the University of Washington Center
for Genomics and Public Health initiated a project to syn-
thesize information about asthma genomics, to examine
its relevance to public health research and practice, and to
communicate findings to a public health practice audience.
This goal was achieved through review of the scientific lit-
erature, formation of a working group, and consultations
with professionals and community organizations. This
paper describes the methods used to conduct these profes-
sional and community consultations, referred to as the
asthma consultative process, and discusses the lessons
learned from this activity.
Introduction
There is widespread enthusiasm that findings from the
Human Genome Project will significantly shape the public
health practice of the future (1). In recent years, genomic
research has provided new insights into the etiology and
pathogenesis of asthma, a major public health burden in
the United States. However, while genomics research is
leading to new hypotheses about asthma onset and pro-
gression, and may alter how asthma is understood at the
molecular level, it is not yet clear if and how genomics can
be used in asthma prevention, diagnosis, and manage-
ment. Additionally, the volume of new literature poses a
potential barrier for professionals who wish to stay abreast
of current findings. To translate basic sciences research
findings into relevant applications, it will be important to
gather and synthesize the rapidly changing body of infor-
mation about asthma genomics and to consider research
findings in the context of public health principles. Thus, a
multidisciplinary approach for summarizing, evaluating,
and translating knowledge in asthma genomics for public
health practice is needed. To meet this challenge, the
University of Washington Center for Genomics and Public
Health (UWCGPH) developed a process for summarizing
and considering potential implications of asthma genomics
within the broad context of public health practice. This
paper describes the methods used to conduct professional
and community consultations, referred to as the asthma
consultative process, and discusses the lessons learned
from this activity.
Laying the Groundwork for the Asthma
Consultative Process
In December 2002, the UWCGPH initiated a project
with support from the Centers for Disease Control and
Prevention’s (CDC’s) Office of Genomics and Disease
Prevention (OGDP) and National Center for
Environmental Health (NCEH) to gather and synthesize
information about asthma genomics, to examine its rele-
vance to public health research and practice, and to trans-
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late findings into language appropriate for an audience of
public health practitioners. The UWCGPH identified a
need to examine the knowledge base in asthma genomics
and to involve public health and genomics experts in the
project to accomplish these goals. The UWCGPH met
these needs through a yearlong project that involved an
extensive review of the literature, the formation of a work-
ing group, and the asthma consultative process.
The project began with a review of the published scien-
tific literature on asthma genomics. The UWCGPH identi-
fied relevant literature through an initial electronic search
of PubMed using the search terms “asthma genomics
(gene/genetic/genetics),” restricting the search to studies in
humans and articles written in English. This literature
base was used to identify current findings relevant to the
integration of genomics into public health research and
practice related to asthma. Periodic reviews of the litera-
ture were conducted, and additional publications, includ-
ing local, national, and federal documents on asthma, were
identified throughout the project period. Following the ini-
tial literature search, the UWCGPH drafted a document
summarizing current asthma research priorities and evi-
dence of genetic contributors to asthma risk.
In addition to the literature review, the UWCGPH
formed a working group of 12 professionals knowledgeable
in asthma, genomics, and public health practice who con-
tributed expert opinion, provided guidance on how to
structure consultations, and helped formulate project find-
ings. Members of the group were selected to ensure broad
representation of public health interests, including
research and practice at the state and national levels.
Asthma Consultative Frameworks
The Asthma Working Group developed two frameworks:
1) the translational pathway and 2) a matrix of perspec-
tives and health interventions. Both frameworks were
used to define stakeholders with an interest in genomics
and to broadly characterize types of health care interven-
tions in which genomics could be used. These frameworks
also served as guides for focusing consultations to specific
areas of expertise or practice. The translational pathway
(Figure 1) served to illustrate translation of scientific find-
ings into public health practice and to emphasize the
importance of cross-disciplinary interactions in this
process. Importantly, this pathway encouraged consult-
ants to view their work as part of a broader effort to use
genomics advances to improve health outcomes.
The broad spectrum of public health research and prac-
tice occurs in many settings, draws upon several disci-
plines, and affects the population’s health through several
means. Figure 2 presents a matrix of perspectives and
health interventions, outlining four key opportunities for
health intervention at different stages of disease preven-
tion and management: population-based prevention, risk-
based prevention, diagnosis, and management. In addition
to designating areas of intervention, the framework out-
lines the perspectives of groups who have a vested interest
in the research and use of genomics for health care pur-
poses: individuals with asthma and their family members,
communities, researchers, health care professionals, com-
mercial developers, and public health practitioners. This
framework was used to create discussion probes
(Appendix) for the consultations and also helped guide the
selection of experts who participated in the asthma con-
sultative process.
Asthma Consultative Process
The primary purpose of the asthma consultative process
was to supplement scientific evidence identified in the
medical literature and to provide comment on the poten-
tial implications genomics may have on public health
efforts in asthma. The selection of consultants was guided
by the goal of representing a broad range of perspectives.
Therefore, we conducted a series of consultations with a
variety of professionals and members of public organiza-
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Figure 1. Translational pathway, which serves to illustrate translation of sci-
entific findings into public health practice.tions. The process was an iterative one in which the
UWCGPH consulted with individuals and, after each
round of consultation, incorporated expert commentary
into a working document.
Professional consultant sampling
We sought consultation with professionals involved in
asthma or genomics research and medical or public health
practice. Experts were identified using a snowball sam-
pling technique, beginning with Seattle area researchers,
health care providers, and public health practitioners
identified by the working group (2). These consultants
were asked to recommend additional local and national
experts; additional experts were sought until no new
experts were identified. A total of 47 professionals who
represented a broad range of organizations, disciplines,
and interests participated in the asthma consultative
process. This total does not include the 12 members of the
Asthma Working Group.
Professional consultant format
Consultations were conducted by two authors (Burke
and Harrison) between January and September 2003
through telephone or in-person key informant interviews
and group discussions. Consultations began with a
description of the project, including both frameworks,
either formally through a PowerPoint presentation for
group consultations or informally for individual or small
group discussions. During consultations, approximately 30
minutes to two hours in duration, participants were asked
to comment on the frameworks and to address a set of
open-ended questions developed by the working group.
The questions focused on the potential implications
genomics may have for asthma prevention, diagnosis, and
management. Written notes were taken and group discus-
sions were tape-recorded with the permission of partici-
pants. Some consultants requested additional background
materials, including review papers, prior to consultative
meetings.
Community consultant sampling
Initial efforts to solicit expert opinion were directed
toward professionals working in scientific, public health,
or medical fields. However, as indicated in the framework,
the perspective of community members is also vital to inte-
grating genomics into public health and medical practice.
The working group first identified local community organ-
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Perspectives
Patient and family
Community
Researcher
Healthcare professional
Commercial developer
Public health practitioner
Population-based 
prevention
Population-based inter-
vention or detection
efforts to avoid or delay
asthma onset
Risk-based prevention
Intervention efforts
targeted to individuals
with susceptibilities to
asthma to avoid or
delay asthma onset
Diagnosis
Identification of asth-
ma subtypes and iden-
tification of individuals
with asthma, including
distinguishing asthma
from other respiratory
diseases
Management
Interventions to reduce
disease burden of
asthma, including
pharmaceutical and
other therapeutics,
environmental modifi-
cation, and behavioral
mechanisms
Interventions
Figure 2. A matrix of perspectives and health interventions, which outlines four key opportunities for health interventions at different stages of disease pre-
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izations with an interest in asthma. The UWCGPH con-
tacted each organization to assess its interest in partici-
pating in the asthma consultative process. A representa-
tive from the organization then approached the group’s
members and asked if they would be willing to participate
in a group discussion about genomics and asthma.
Because of time and funding constraints, only a subset of
organizations identified by the working group were asked
to participate in the process. Three community groups,
including 18 community members, participated in the
group consultations between September and October
2003. Approval for community consultations was obtained
by the University of Washington’s Human Subjects
Division.
Community consultants format
The UWCGPH worked with the community contacts to
schedule the group meetings, to discuss the meeting envi-
ronment, and to learn about the needs and interests of
each group. A total of three community groups were con-
sulted at three separate meetings held in the evenings.
Foreign language translators were hired to assist with dis-
cussions for two meetings and to translate consent forms
distributed to participants. Written notes taken by the
UWCGPH were used to summarize discussions. Sessions
were not tape-recorded.
The format for community consultations differed slight-
ly from professional consultations. Community consulta-
tions consisted of group discussions led by a member of the
UWCGPH and a representative from each organization.
Each meeting began with a description of the project, fol-
lowed by a general discussion about asthma and genomics.
Participants were then read one to three hypothetical sce-
narios illustrating potential asthma-related uses of genet-
ic information. The hypothetical scenarios were developed
by the UWCGPH based on input provided by professional
consultants about areas of asthma genomics that could
potentially lead to health care applications. Topics repre-
sented by the scenarios were pharmacogenomics, newborn
screening to identify susceptible individuals for possible
prevention efforts, and policy development. Policy develop-
ment centered on the use of genetic susceptibility informa-
tion to assist in setting clean air standards. Scenarios were
presented to the group and were followed by a discussion
period where participants were encouraged to provide
comment on the scenario, including identifying areas of
concern. At the end of each meeting, participants were
asked if they had any questions, were reminded that their
input would be confidential, and were thanked for partici-
pation.
Discussion
The UWCGPH developed the asthma consultative
process to summarize asthma genomics research findings
and examine the implications of these findings for public
health research and practice. Results from this process,
and from the literature review and working group discus-
sions, have been compiled into a final report that is avail-
able from www.uwcgph.org. Briefly, findings suggest that
public health researchers and practitioners can ensure
that genomics research supports public health goals by 1)
facilitating the analysis and communication of research in
asthma genomics, 2) promoting population-based research
that investigates both genetic and environmental risk fac-
tors, and 3) conducting advocacy and outreach to promote
access to genomics-based therapies and support communi-
ty-based participatory research methods.
While the asthma consultative process described here
was framed in the context of public health, it drew from
experts involved in efforts to improve the population’s
health at several organizational levels and across several
disciplines. The diversity of consultants was valuable to
the process because it helped to 1) identify unanticipated
issues that would not have been apparent from a single
perspective or through a literature review alone, 2) identi-
fy unforeseen stakeholders, and 3) reflect the diversity of
public health in our findings.
The asthma consultative process also allowed for a
degree of flexibility. The scheduling of consultations with
experts over several months, rather than at a single meet-
ing, allowed for access to a wider range and greater num-
ber of experts and allowed us to tailor discussions to each
consultant’s area of expertise. Additionally, we were able to
make efficient use of experts’ time by consulting over the
telephone, convening at national conferences, and schedul-
ing group or individual appointments at locations and
dates convenient for consultants. The iterative process also
allowed us to return to issues during the course of the con-
sultation as new insights emerged. Thus, the frameworks
and report developed by the working group were continual-
ly revised after each consultation and over time led to a doc-
ument that served as the basis for the final report.
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opportunities to gauge the level of awareness about public
health genomics and to assist public health practitioners
interested in learning about asthma genomics. Few con-
sultants had considered genomics in the context of public
health practice. In some instances, discussions enabled con-
sultants to create new relationships and exchange ideas,
providing them with opportunities to learn about research
or public health practices and to gain insights into perspec-
tives other than their own. Additionally, the process creat-
ed opportunities for assisting public health practitioners to
learn about asthma genomics. For example, the UWCGPH
provided technical assistance on asthma genomics to three
state health departments and developed Web pages high-
lighting information about asthma genomics as part of the
CDC Public Health Perspective series.
The asthma consultative process also had some limita-
tions. The process was a voluntary one in which experts
were recommended by other consultants. Because of this,
the participation of individuals representing each perspec-
tive could not be guaranteed. For example, a sixth per-
spective, that of the commercial developer, was identified
during initial consultations and was added to the frame-
work. Although individuals representing the commercial
perspective were invited to provide consultations, none
participated in the process. Additionally, resource and
time constraints did not allow us to conduct as compre-
hensive a series of consultations with community groups
as were conducted with professionals. Future efforts are
needed to expand the dialogue about public health
genomics with additional community organizations, asth-
matic individuals and their families, and commercial
developers.
In summary, the asthma consultative process offers an
efficient approach for examining the potential implications
that genomics will have for the field of public health. The
method described in this paper not only enabled the
UWCGPH to review the current state of knowledge in
asthma genomics, but it allowed for opportunities to
engage multiple stakeholders, create linkages among
experts from different disciplines, and generate awareness
about public health genomics.
The collaboration between professionals from multiple
health-related disciplines will be fundamental to bridging
the gap between the identification of genetic contributions
to disease and the development of new genomics-based
interventions to improve health outcomes. In an effort to
promote this important collaboration, the UWCGPH car-
ried out the asthma consultative process. Processes such
as this one can serve to strengthen the capacity to inte-
grate genomics into public health research and practice.
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1. How would you define genomics?
2. Does the framework provided by the translational pathway and the
table provide a useful way of framing the discussion of the implica-
tions of genomics for asthma disease prevention?
* Are there missing perspectives? What different groups/
agencies do you see represented in each perspective?
* Are there alternative ways to approach the problem?
* What perspective(s) do you feel you represent?
3. From your perspective, is genomics currently a factor in asthma
care? If yes, does it affect:
* Universal prevention measures
* Risk-based prevention measures
* Diagnosis
* Management
* Public health efforts
If no, why not and what would make it applicable? Are there
barriers?
4. Is genomics likely to have an impact on asthma care in the future?
If yes, will it affect:
* Universal prevention measures
* Risk-based prevention measures
* Diagnosis
* Management
* Public health efforts
If no, why not and what would make it applicable? Are there
barriers?
5. What research is most important in the area of asthma genomics?
Why is this research most important?
* What are the barriers to accomplishing this research?
* What could be done to encourage this research?
* How could this research contribute to improved asthma 
outcomes?
6. Are there potential harms related to asthma genomics?
* If yes:
o What are they?
o Are there potential mechanisms/solutions to prevent 
or control these harms?
* If no, why not?
7. Does your own work involve genomics?
* If yes, how?
* If no, do you expect it to do so in the future?
8. Do state agencies and the CDC have a role in the application of
genomic information or research to asthma disease prevention?
* If yes, how?
* If no, why and do you expect it to do so in the future?
Appendix. Consultation Guide Discussion Probes
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